Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Molindone - Supernus Pharmaceuticals

Drug Profile

Molindone - Supernus Pharmaceuticals

Alternative Names: AFX 2201; EN-1733A; Molindone hydrochloride; Molindone XR; SPN-810; SPN-810M; Zalvari

Latest Information Update: 11 Apr 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Afecta Pharmaceuticals
  • Developer Supernus Pharmaceuticals
  • Class Antipsychotics; Behavioural disorder therapies; Indoles; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Attention-deficit hyperactivity disorder

Most Recent Events

  • 11 Apr 2023 Supernus in licensed Molidone from Afecta Pharmaceuticals before April 2023 (Afecta Pharmaceuticals, April 2023)
  • 22 Oct 2020 Supernus Pharmaceuticals terminates a phase III trial in Attention deficit hyperactivity disorder in USA (NCT03597503)
  • 01 Apr 2020 Supernus Pharmaceuticals completes the phase III extension CHIME 4 trial in Attention deficit hyperactivity disorder (In children, Adjunctive treatment) in USA (NCT02691182)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top